For example, whereas CKD and group 3 patients would likely benefit from broad immune suppression and targeted therapies like IL-6 blockade, these same treatments are unlikely to show the same effect in group 2 patients and may instead hinder protective antiviral adaptive immune responses. Here, IL6 is linked to chronic kidney disease.